核酸治療薬CDMO市場：治療薬タイプ、サービスタイプ、治療用途、エンドユーザー別-2025-2030年世界予測

核酸治療薬CDMO市場は、2024年に107億7,000万米ドルと評価され、2025年にはCAGR 11.42%で120億米ドルに成長し、2030年には206億2,000万米ドルに達すると予測されています。

核酸治療薬は、現代医学を再定義する革新的な手法として登場しました。開発・製造受託機関（CDMO）の状況は、先進的な遺伝子治療や画期的な治療によって設定された厳格な基準を満たすために急速に進化しています。最近の科学的な飛躍的進歩と規制の枠組みの拡大が相まって、技術革新と専門的な製造サービスに対する緊急のニーズが高まっています。堅牢な分析試験、精密な品質管理、カスタム製造ソリューションの統合により、これらの組織はDNAやRNAをベースとする治療法の複雑な要求をサポートできるようになりました。

さらに、遺伝性疾患、感染症、腫瘍学にまたがる治療用途の拡大は、研究のブレークスルーと臨床ニーズが鋭く交差していることを示しています。この市場の物語は、学界、バイオテクノロジー、製薬業界にわたる協力的パートナーシップの重要性を浮き彫りにしているだけでなく、新規のバイオ治療分子を扱うために従来の製造手法を適応させることの重要性も強調しています。市場のファンダメンタルズが変化する中、意思決定者は新技術を活用し、生産効率を最適化する機会を検討しています。

核酸治療薬の進化は、課題と大きな機会の両方を提示しています。精密さ、スケーラビリティ、迅速なイノベーションへの要求が高まる中、CDMOは科学的創造性と製造の専門知識の合流点にユニークな位置づけにあります。この包括的な調査により、市場セグメンテーション、地域ダイナミックス、主要業界プレイヤーの影響力に関する詳細な洞察が可能となり、戦略的意思決定を支援するための権威ある概要が提供されます。

核酸治療薬の情勢を形成する変革的変化

核酸治療薬市場は、科学的イノベーション、デジタル変革、進化する規制環境に牽引され、劇的な変化を経験しています。従来の医薬品開発のパラダイムは、俊敏な製造プロセスと統合技術ソリューションによって再定義されつつあります。RNAおよびDNA治療薬の発見ペースが加速しているため、高い有効性と信頼性を兼ね備えた製品を提供できる新たな製造手法が必要とされています。

利害関係者は、従来の低分子製造から、より微妙な生物学的製造戦略への移行を目の当たりにしています。この転換は、正確な品質管理を保証する高度な分析プラットフォームと強化された工程管理システムの採用によって特徴付けられます。さらに、遺伝子編集技術やメッセンジャーRNA技術を含む治療方法の急速な拡大により、規制遵守を維持しながら迅速に生産規模を拡大できる、機敏で堅牢な製造パートナーシップに対する需要が高まっています。

同時に、マーケットプレースは研究と生産方法のデジタル変革を受け入れています。クラウドベースのデータ分析とリアルタイムのモニタリングが生産ワークフローに統合され、事前調整と継続的改善が可能になりつつあります。こうした変化は、市場投入までの時間を大幅に短縮し、生物製剤製造に内在する従来のボトルネックのいくつかを克服することで、この分野をさらなる高みへと押し上げています。

競合要因が競合情勢を再定義しています。このシフトは単に技術的なものだけでなく、文化的なものでもあり、コラボレーション、リスク管理、最先端の製造インフラへの戦略的投資に改めて焦点を当てることが求められています。

市場セグメンテーションの洞察が市場イノベーションを促進する

核酸治療薬市場をセグメント別に分析すると、多様なニーズと専門能力に対応する多面的な構造が明らかになります。同市場は治療薬のタイプ別に分類され、DNAとRNAの両方の様式が調査しています。DNA治療薬は伝統的に安定性と実績を提供してきたが、RNA治療薬は迅速な開発サイクルと調節可能な遺伝子発現を提供し、境界を押し広げ続けています。この2つの経路は、確立されたプロトコールと新たなイノベーションの戦略的バランスを表しています。

サービスタイプのセグメンテーションは、分析試験と品質管理、製造、パッケージングと流通、プロセス開発と最適化などの分野をさらに明確にします。各サービス・カテゴリーは、治療が効果的であるだけでなく、確実に提供されることを保証する上で極めて重要な役割を果たしています。分析試験と品質管理は、規制機関がより厳しい基準を課すようになったため、ますます重要になってきており、製造能力は精密工学と自動化の統合によって強化されています。パッケージングと流通は、プロセス開発と相まって、研究所のイノベーションから患者へのデリバリーまで、シームレスな連続性を提供しています。

治療への応用を検討する場合、遺伝子疾患、感染症、神経疾患、腫瘍学、希少疾患など、様々な臨床分野から洞察が引き出されます。それぞれの応用分野には、独自の課題と機会があり、それが研究開発戦略の原動力となっています。例えば、腫瘍学や神経疾患における治療パラダイムの進化は、従来のドラッグデリバリーシステムの再検討を促し、新規で的を絞った介入の創出を促しています。

さらに、学術・研究機関、バイオテクノロジー企業、製薬会社にまたがるエンドユーザー別のセグメントは、核酸治療の広範な広がりを示しています。学術分野は基礎研究を推進し、バイオテクノロジー分野は発見を迅速に臨床応用に結びつける。一方、製薬会社は、これらのイノベーションを世界市場にもたらし、ますます競争環境が激化する中で、アクセス性と持続的成長を確保しています。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界的に遺伝性疾患の有病率が増加
    • 個別化医療と標的遺伝子治療の需要の高まり
    • 医薬品およびバイオテクノロジー分野における研究開発活動の拡大
  • 抑制要因
    • 核酸医薬品の製造における厳格な規制遵守
  • 機会
    • CDMO環境における高度な治療アプリケーションのための高度な核酸安定化技術と分析試験プラットフォームの活用
    • mRNAベースのワクチンと治療薬の継続的な開発
  • 課題
    • 核酸医薬品開発に特化した熟練した専門家の不足
• 市場セグメンテーション分析
  • サービスタイプ：純度と効力の分析試験と品質管理サービスへの関心が高まっています
  • エンドユーザー：学術調査機関における核酸治療薬CDMOの活用拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 核酸治療薬CDMO市場治療薬の種類別

• DNAセラピューティクス
• RNAセラピューティクス

第7章 核酸治療薬CDMO市場：サービスタイプ別

• 分析試験と品質管理
• 製造業
• 包装と配送
• プロセス開発と最適化

第8章 核酸治療薬CDMO市場治療用途

• 遺伝性疾患
• 感染症
• 神経疾患
• 腫瘍学
• 希少疾患

第9章 核酸治療薬CDMO市場：エンドユーザー別

• 学術調査機関
• バイオテクノロジー企業
• 製薬会社

第10章 南北アメリカの核酸治療薬CDMO市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の核酸治療薬CDMO市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの核酸治療薬CDMO市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AGC Biologics Inc.
• Agilent Technologies, Inc.
• Ajinomoto Bio-Pharma Services
• Almac Group Ltd.
• Biomay AG
• BioSpring GmbH
• Catalent, Inc.
• Charles River Laboratories International, Inc.
• CordenPharma International GmbH
• Creative Biogene
• Danaher Corporation
• Eurofins Scientific SE
• Evonik Industries AG
• GenScript Biotech Corporation
• Lonza Group Ltd.
• Polypeptide Group AG
• Recipharm AB
• Rentschler Biopharma SE
• Samsung Biologics
• The Scripps Research Institute
• Touchlight Group
• Univercells Group
• WuXi AppTec Co., Ltd.

LIST OF FIGURES

• FIGURE 1. NUCLEIC ACID THERAPEUTICS CDMO MARKET MULTI-CURRENCY
• FIGURE 2. NUCLEIC ACID THERAPEUTICS CDMO MARKET MULTI-LANGUAGE
• FIGURE 3. NUCLEIC ACID THERAPEUTICS CDMO MARKET RESEARCH PROCESS
• FIGURE 4. NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 17. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 19. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 25. NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. NUCLEIC ACID THERAPEUTICS CDMO MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NUCLEIC ACID THERAPEUTICS CDMO MARKET DYNAMICS
• TABLE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 38. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 39. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 40. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 41. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 60. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 61. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 62. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 63. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 64. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 65. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 66. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 67. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 133. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 134. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 135. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 136. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 149. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 150. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 151. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 152. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 153. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 154. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 155. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 156. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 193. NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 194. NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2024

The Nucleic Acid Therapeutics CDMO Market was valued at USD 10.77 billion in 2024 and is projected to grow to USD 12.00 billion in 2025, with a CAGR of 11.42%, reaching USD 20.62 billion by 2030.

Nucleic acid therapeutics have emerged as transformative modalities redefining modern medicine. The landscape of contract development and manufacturing organizations (CDMOs) is rapidly evolving to meet the rigorous standards set by advanced gene therapies and revolutionary treatments. Recent scientific breakthroughs, combined with an expanding regulatory framework, have driven both innovation and an urgent need for specialized manufacturing services. The integration of robust analytical testing, precision quality control, and custom manufacturing solutions has enabled these organizations to support the complex demands of DNA- and RNA-based therapies.

Furthermore, the expansion of therapeutic applications across genetic disorders, infectious diseases, and oncology demonstrates a keen intersection between research breakthroughs and clinical needs. This market narrative not only highlights the importance of collaborative partnerships across academia, biotechnology, and pharmaceutical industries but also underscores the significance of adapting traditional manufacturing methodologies to handle novel biotherapeutic molecules. As market fundamentals shift, decision-makers are examining opportunities to leverage new technologies and optimize production efficiency.

The evolution of nucleic acid therapeutics presents both challenges and substantial opportunities. With increasing demands for precision, scalability, and rapid innovation, CDMOs are positioned uniquely at the confluence of scientific creativity and production expertise. This comprehensive exploration sets the stage for in-depth insights into market segmentation, regional dynamics, and the influence of key industry players, providing an authoritative overview structured to support strategic decision-making.

Transformative Shifts Reshaping the Nucleic Acid Therapeutics Landscape

The nucleic acid therapeutics market is experiencing dramatic shifts driven by scientific innovation, digital transformation, and evolving regulatory environments. Traditional drug development paradigms are being redefined by agile manufacturing processes and integrated technology solutions. The accelerating pace of RNA and DNA therapeutic discovery has necessitated new production methodologies that can deliver products with both high efficacy and reliability.

Stakeholders are witnessing a transition from conventional small molecule production to more nuanced biological manufacturing strategies. This transformation is characterized by the adoption of advanced analytical platforms and enhanced process control systems that ensure precise quality control. Moreover, the rapid expansion of therapeutic modalities, including gene editing and messenger RNA technologies, has driven demand for agile and robust manufacturing partnerships capable of scaling production swiftly while maintaining regulatory compliance.

Simultaneously, the marketplace is embracing the digital transformation of research and production methods. Cloud-based data analytics and real-time monitoring are being integrated into production workflows, enabling proactive adjustments and continuous improvement. These changes are propelling the sector to greater heights by significantly reducing time-to-market and overcoming some of the traditional bottlenecks inherent in biologics manufacturing.

Collectively, these factors are redefining competitive strategies across the landscape. The shift is not simply technological but cultural, demanding a renewed focus on collaboration, risk management, and strategic investment in state-of-the-art manufacturing infrastructure.

Key Segmentation Insights Driving Market Innovation

The segmented analysis of the nucleic acid therapeutics market reveals a multifaceted structure that caters to diverse needs and specialized capabilities. The market is dichotomized by therapeutics type, studying both DNA and RNA modalities. DNA therapeutics have traditionally provided stability and a proven track record, while RNA therapeutics continue to push boundaries, offering rapid development cycles and tunable gene expression. This dual pathway represents a strategic balance between established protocols and emerging innovations.

Service type segmentation further illuminates areas such as analytical testing and quality control, manufacturing, packaging and distribution, and process development and optimization. Each service category plays a pivotal role in ensuring therapies are not only effective but also reliably delivered. Analytical testing and quality control have become increasingly critical as regulatory bodies enforce stricter criteria, while manufacturing capabilities are being enhanced by the integration of precision engineering and automation. Packaging and distribution, coupled with process development, provide a seamless continuum from laboratory innovation to patient delivery.

When examining therapeutic applications, insights are drawn from various clinical sectors including genetic disorders, infectious diseases, neurological disorders, oncology, and rare disorders. Each application area carries unique challenges and opportunities that drive tailored research and development strategies. The evolution of treatment paradigms in oncology and neurological disorders, for instance, is prompting a re-examination of traditional drug delivery systems and inspiring the creation of novel, targeted interventions.

Moreover, the segment based on end users-spanning academic and research institutes, biotechnology firms, and pharmaceutical companies-exemplifies the extensive reach of nucleic acid therapies. The academic realm propels foundational research, while the biotechnology sector rapidly translates discoveries into clinical applications. Pharmaceutical companies, on the other hand, bring these innovations to a global market, ensuring accessibility and sustained growth in an increasingly competitive environment.

Based on Therapeutics Type, market is studied across DNA Therapeutics and RNA Therapeutics.

Based on Service Type, market is studied across Analytical Testing & Quality Control, Manufacturing, Packaging & Distribution, and Process Development & Optimization.

Based on Therapeutic Applications, market is studied across Genetic Disorders, Infectious Diseases, Neurological Disorders, Oncology, and Rare Disorders.

Based on End User, market is studied across Academic & Research Institutes, Biotechnology Firms, and Pharmaceutical Companies.

Key Regional Insights Across Global Markets

The global perspective of nucleic acid therapeutics uncovers significant regional variations that highlight both unique opportunities and sector-specific challenges. In the Americas, advanced research infrastructures and a robust funding environment have fostered an ecosystem where innovation thrives alongside regulatory excellence. This region continues to lead in terms of clinical trials and state-of-the-art manufacturing facilities, making it a hotspot for next-generation therapeutic discovery and production.

Across Europe, the Middle East, and Africa, there is a pronounced emphasis on harmonizing regulatory standards while fostering an environment conducive to public-private partnerships. European markets, in particular, are noted for stringent compliance and quality benchmarks, which drive industry standards upward. The Middle East and Africa are witnessing increasing investments in biotechnological research, motivated by a growing need to address regional health challenges and tap into emerging talent pools. This diverse region articulates a unique blend of legacy expertise and innovative agility.

In Asia-Pacific, rapid economic development and substantial investments in research and development are redefining the landscape. The region benefits from a mix of established industrial bases and nimble start-ups, which together contribute to a competitive production and innovation environment. The surge in regulatory reforms is further catalyzing innovation, ensuring that manufacturing processes keep pace with global benchmarks. This dynamic region not only supports large-scale clinical development but also serves as a critical hub for supply chain optimization and operational excellence across the nucleic acid therapeutics market.

These region-specific insights reinforce the view that a one-size-fits-all approach is untenable. Instead, tailored strategies that account for local market dynamics, resource availability, and regulatory environments are essential for tapping the diverse global potential of nucleic acid therapeutics.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Leading the Charge in Therapeutics Innovation

The competitive landscape is defined by a cadre of leading companies whose innovative approaches are setting new standards in the nucleic acid therapeutics market. Firms such as AGC Biologics Inc. and Agilent Technologies, Inc. are recognized for their commitment to integrating advanced analytics with meticulous quality control processes. Ajinomoto Bio-Pharma Services and Almac Group Ltd. have carved out reputations for excellence in manufacturing and process optimization, consistently delivering reliable solutions that meet rigorous industry standards.

Equally influential are organizations like Biomay AG and BioSpring GmbH, which have leveraged cutting-edge technologies to optimize both packaging and distribution channels. Catalent, Inc. and Charles River Laboratories International, Inc. have been instrumental in refining manufacturing protocols and streamlining analytical testing methodologies that enhance overall product reliability. Industry leaders such as CordenPharma International GmbH and Creative Biogene exemplify the ability to balance high-volume production with precision customization.

Danaher Corporation and Eurofins Scientific SE further underscore the critical role of innovative testing and quality assurance procedures, while companies including Evonik Industries AG and GenScript Biotech Corporation have accelerated process development and optimization. Lonza Group Ltd. and Polypeptide Group AG stand out for their scalable manufacturing solutions, ensuring seamless transitions from bench to market. Other key players, including Recipharm AB and Rentschler Biopharma SE, have continued to drive efficiency and innovation in both traditional and next-generation therapeutic production.

Samsung Biologics and The Scripps Research Institute illustrate the vital interconnectedness of research and manufacturing, a trait shared by Touchlight Group, Univercells Group, and WuXi AppTec Co., Ltd. Their combined efforts are not only redefining production paradigms but are also instrumental in pushing the boundaries of what is scientifically and commercially possible in the realm of nucleic acid therapeutics.

The report delves into recent significant developments in the Nucleic Acid Therapeutics CDMO Market, highlighting leading vendors and their innovative profiles. These include AGC Biologics Inc., Agilent Technologies, Inc., Ajinomoto Bio-Pharma Services, Almac Group Ltd., Biomay AG, BioSpring GmbH, Catalent, Inc., Charles River Laboratories International, Inc., CordenPharma International GmbH, Creative Biogene, Danaher Corporation, Eurofins Scientific SE, Evonik Industries AG, GenScript Biotech Corporation, Lonza Group Ltd., Polypeptide Group AG, Recipharm AB, Rentschler Biopharma SE, Samsung Biologics, The Scripps Research Institute, Touchlight Group, Univercells Group, and WuXi AppTec Co., Ltd.. Actionable Recommendations for Industry Leaders in Therapeutics

Industry leaders must adopt a multidimensional strategy to navigate the shifting landscape of nucleic acid therapeutics effectively. It is crucial to invest in state-of-the-art manufacturing infrastructure, ensuring seamless integration of digital analytics with process automation. Firms should proactively engage with regulatory bodies to remain ahead of compliance curves, thus securing a competitive edge in innovation and market penetration.

Collaboration remains a powerful tool in this sector. Establishing strategic partnerships with research institutions, biotechnology innovators, and global pharmaceutical companies can help accelerate product development and broaden market reach. Emphasis on robust risk management strategies, coupled with the adoption of advanced manufacturing platforms, will serve as catalysts for operational excellence. Leaders in the field are encouraged to leverage emerging technologies that promise enhanced scalability and faster time-to-market, aligning production capabilities with the rapidly evolving clinical demands.

Lastly, maintaining an agile mindset is critical as market dynamics continue to evolve. Organizations that invest in continual improvement and foster an environment of cross-disciplinary innovation will be best positioned to capitalize on the emerging opportunities within this space.

Conclusion: Embracing Change in Nucleic Acid Therapeutics

In conclusion, the advancement of nucleic acid therapeutics represents a significant leap forward in modern medicine. The market is witnessing an era of transformative change, driven by innovative scientific breakthroughs, strategic segmentation insights, and a competitive ecosystem dominated by leading industry players. The evolving landscape requires a nuanced understanding of the interplay between technology, regulation, and market dynamics.

This comprehensive analysis underscores the importance of adopting forward-thinking strategies and leveraging global insights to build resilient and efficient production pipelines. The future of nucleic acid therapeutics lies in the hands of those who not only embrace change but also proactively drive its evolution through innovation, collaboration, and strategic investment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of genetic disorders globally
    • 5.1.1.2. Rising demand for personalized medicine and targeted gene therapies
    • 5.1.1.3. Expansion of research and development activities in pharmaceutical and biotechnology sectors
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent regulatory compliance in production of nucleic acid therapeutics
  • 5.1.3. Opportunities
    • 5.1.3.1. Leveraging advanced nucleic acid stabilization techniques and analytical testing platforms for advanced therapeutic applications in CDMO settings
    • 5.1.3.2. Ongoing development of mRNA-based vaccines and therapeutics
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of skilled professionals specialized in nucleic acid therapeutics development
• 5.2. Market Segmentation Analysis
  • 5.2.1. Service Type: Increasing preference for analytical testing & quality control services for their purity, and potency
  • 5.2.2. End User: Expanding utilization of nucleic acid therapeutics CDMO in academic & research institutes
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Nucleic Acid Therapeutics CDMO Market, by Therapeutics Type

• 6.1. Introduction
• 6.2. DNA Therapeutics
• 6.3. RNA Therapeutics

7. Nucleic Acid Therapeutics CDMO Market, by Service Type

• 7.1. Introduction
• 7.2. Analytical Testing & Quality Control
• 7.3. Manufacturing
• 7.4. Packaging & Distribution
• 7.5. Process Development & Optimization

8. Nucleic Acid Therapeutics CDMO Market, by Therapeutic Applications

• 8.1. Introduction
• 8.2. Genetic Disorders
• 8.3. Infectious Diseases
• 8.4. Neurological Disorders
• 8.5. Oncology
• 8.6. Rare Disorders

9. Nucleic Acid Therapeutics CDMO Market, by End User

• 9.1. Introduction
• 9.2. Academic & Research Institutes
• 9.3. Biotechnology Firms
• 9.4. Pharmaceutical Companies

10. Americas Nucleic Acid Therapeutics CDMO Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Nucleic Acid Therapeutics CDMO Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Nucleic Acid Therapeutics CDMO Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2024
• 13.2. FPNV Positioning Matrix, 2024
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Maravai LifeSciences broadens its nucleic acid therapeutics pipeline by acquiring Officinae Bio's DNA and RNA business
  • 13.3.2. GSK forges strategic licensing deal with Touchlight to access advanced doggybone DNA technology
  • 13.3.3. FUJIFILM Toyama Chemical and Synplogen Forge Alliance to Enhance mRNA Therapeutics Production
  • 13.3.4. Exothera Launches Advanced RNA Therapeutics Platform 'Ntensify' in North America, Streamlining Nucleic Acid Drug Development
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AGC Biologics Inc.
• 2. Agilent Technologies, Inc.
• 3. Ajinomoto Bio-Pharma Services
• 4. Almac Group Ltd.
• 5. Biomay AG
• 6. BioSpring GmbH
• 7. Catalent, Inc.
• 8. Charles River Laboratories International, Inc.
• 9. CordenPharma International GmbH
• 10. Creative Biogene
• 11. Danaher Corporation
• 12. Eurofins Scientific SE
• 13. Evonik Industries AG
• 14. GenScript Biotech Corporation
• 15. Lonza Group Ltd.
• 16. Polypeptide Group AG
• 17. Recipharm AB
• 18. Rentschler Biopharma SE
• 19. Samsung Biologics
• 20. The Scripps Research Institute
• 21. Touchlight Group
• 22. Univercells Group
• 23. WuXi AppTec Co., Ltd.